Metavia Inc. (MTVA) - Q2 2026 10-Q Summary
Business Context and Reporting Period
Metavia Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for cardiometabolic diseases, specifically metabolic dysfunction-associated steatohepatitis (MASH) and obesity. The company operates two primary programs: vanoglipel (GPR119 agonist) and DA-1726 (GLP-1/GCGR dual agonist). This report covers the quarterly period ended June 30, 2026.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(5.32) million | $(9.14) million | $(7.67) million |
| Loss Per Share (Diluted) | $(0.90) | $(1.69) | $(6.59) |
| Operating Expenses | $5.39 million | $9.41 million | $8.19 million |
| Cash and Cash Equivalents | $12.63 million (as of June 30, 2026) | ||
| Accumulated Deficit | $(158.0) million (as of June 30, 2026) | ||
| Net Cash Used in Operating Activities | $(8.02) million (YTD 2026) | ||
| Net Cash Provided by Financing Activities | $10.38 million (YTD 2026) |
Material Changes vs. Prior Period
- Increased R&D Spend: Research and development expenses rose 50% quarter-over-quarter (Q2 2026 vs. Q2 2025) and 20% year-to-date. This increase is primarily driven by the Phase 1 clinical trial for DA-1726, specifically Part 3a and 3b titration studies initiated in April 2026.
- Share Count Expansion: The weighted average shares outstanding increased significantly from ~1.16 million (YTD 2025) to ~5.40 million (YTD 2026) due to an underwritten public offering in January 2026, an At-The-Market (ATM) offering, and warrant exercises.
- Related Party Payables: The payable to Dong-A ST Co., Ltd. (related party) decreased from $3.31 million to $1.90 million, though $1.4 million remains unpaid with extended terms.
- Warrant Liability Fair Value: The company recorded a gain of $0.11 million YTD 2026 from the change in fair value of warrant liabilities, compared to a $0.25 million gain in the prior year period.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern within one year. With $12.6 million in cash and a burn rate of approximately $8 million over six months, the company expects to continue incurring losses and requires additional financing.
- Clinical Milestones:
- DA-1726: Dose titration in the Phase 1 Part 3 study was completed in July 2026. Data readouts for Parts 3a and 3b are planned for Q4 2026. Recent data presented at EASL 2026 showed up to 9.1% mean body weight reduction.
- Vanoglipel: The Clinical Study Report for the Phase 2a trial is expected to be finalized in Q4 2026. The company is working to schedule an end-of-Phase 2 meeting with the FDA.
- Capital Strategy: The company plans to fund operations through equity offerings, debt financing, or warrant exercises. In January 2026, it raised $7.1 million net from a public offering. In July 2026, the ATM program size was increased to $4.0 million.
- Risks: Key risks include the inability to secure additional funding, potential dilution to shareholders, and the uncertainty of clinical trial outcomes and regulatory approvals.
Investor Verification Checklist
- Cash Runway: Verify the current cash burn rate against the $12.6 million cash balance to assess the immediate need for capital raises.
- Related Party Transactions: Review the terms of the Shared Services Agreement with Dong-A ST, specifically the $1.4 million unpaid invoice and the 4.6% interest accrual.
- Warrant Dilution: Assess the impact of the ~8.96 million outstanding warrants (including Series C and D) on future share count and potential dilution upon exercise.
- Clinical Data Readouts: Monitor the Q4 2026 data readouts for DA-1726 (Phase 1 Part 3) and vanoglipel (Phase 2a), as these are critical for future funding and valuation.
- ATM Program Utilization: Track the utilization of the expanded $4.0 million ATM program to gauge management's confidence in the stock price and capital needs.